The Claim

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes combined resolution of steatohepatitis and reduction in liver fibrosis in approximately 32.7% of patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3, compared to 16.1% with placebo, at 72 weeks.

Source: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Semaglutide, a drug injected once a week, improves both liver inflammation and scarring in about one-third of people with a type of fatty liver disease called MASH who have moderate liver fibrosis. This effect is twice as common as with a placebo.

See the scientific wording

Once-weekly subcutaneous semaglutide at a dose of 2.4 mg causes combined resolution of steatohepatitis and reduction in liver fibrosis in approximately 32.7% of patients with MASH and fibrosis stage 2 or 3, compared to 16.1% with placebo (absolute difference 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001) at 72 weeks, indicating that semaglutide can simultaneously improve both disease activity and fibrosis.

Why this might work

Semaglutide is a medicine that helps the liver get rid of extra fat and harmful substances. In MASH, the liver makes too many ceramides and oxalates, which cause inflammation and scarring. Semaglutide stops the liver from making these harmful molecules, and it also keeps the liver's blood vessels healthy. This makes the swelling go down and the scarring heal.

Hypothetical mechanismbased on 1 study

What the research says

1 study

  1. Study: Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

    The study found that about 33 out of 100 people taking semaglutide had both less liver inflammation and less scarring, compared to about 16 out of 100 on placebo, which is exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.